AU2012216435B8 — Piperidine derivatives as NK1 antagonists
Assigned to Opko Health Inc · Expires 2015-02-19 · 11y expired
What this patent protects
OF THE INVENTION A compound having the general structure shown in Formula I: R' R2 Ar2 R4,N )n 5 Ar 0 R (I) or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example 10 various physiological d…
USPTO Abstract
OF THE INVENTION A compound having the general structure shown in Formula I: R' R2 Ar2 R4,N )n 5 Ar 0 R (I) or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example 10 various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.